NOT FOR CLINICAL USE / SYNTHETIC DEMO — Not medical advice. Not FDA-cleared. Gate 3 is not signed. Predicted odds are from published studies only.
Workspace · Late toxicity printouts
Patient-education printouts for adult RT fields. Sections match the follow-up note: Acute toxicities · Late toxicities · Named conditions to monitor. Named from ACS radiation body-part pages, the ACS long-term and late-effects page, and already-cited follow-up sources. Cadences are placeholders. Not FDA-cleared. Synthetic demo only.
NOT FOR CLINICAL USE / SYNTHETIC DEMO — Educational estimates only. Not FDA-cleared. Not a diagnosis.
GYN excludes gestational trophoblastic disease. Sarcoma lists bone and soft-tissue as cited algorithm sites. No invented trial percent.
Official empty later-cancer notes
Cited empty sentences only. Not a later-cancer engine. Kidney and thyroid stay unmapped without an invented empty note.
The cited adult brain after-treatment page still has no official later-cancer sentence.
Official copy: there is no standard staging system for leukemia.
Anthracycline and bleomycin stay unnamed as myeloma-specific.
Questions to ask
ACS long-term page lists questions to ask the care team: possible long-term and late effects, whether fertility or second-cancer risk is higher, which cancer screening tests belong later, which specialists should follow those effects, whether cancer rehabilitation could help, and when to call primary care versus cancer care. Those questions are not encoded. Not a screening, fertility, rehab, or specialist-interval engine.
ACS long-term page says not everyone who has cancer treatment gets long-term or late effects. Who does can depend on the cancer type, the type and dose of treatment, side effects during treatment, age at diagnosis, health before treatment, genetics, eating and exercise during and after treatment, care-team expertise, and support from others. Those reasons are not encoded. Not a late-effect risk-score engine.
ACS follow-up-care page lists questions to ask: how to get a treatment summary and follow-up care plan, who is in charge of follow-up, how often visits and which tests or screens belong later, signs of recurrence or a second cancer, and which survivor support services are available. Follow-up may stay with the cancer care team, move to a survivorship clinic, or return to primary care, depending on the cancer type and stage, the treatment, remaining side effects, insurance, and wishes. Those questions and choices are not encoded. Not a visit-interval, screening, or clinic-routing engine.
ACS long-term and follow-up-care lists, named not encoded. Not a fourth printout section.
Treatment summary and care plan
ACS follow-up-care page names what a cancer treatment summary most often includes: diagnosis date; cancer type, including where it started, stage, and grade if known; treatments and dates, including type, dose, and number of cycles; side effects and how they were managed; test results; and names and contacts for the treating doctors. A survivorship care plan most often names remaining treatment, how often follow-up should happen, which tests including screens for other cancers, possible long-term or late effects, and ways to improve overall health. Those named contents are not encoded. Not a records, visit-interval, or screening engine.
ACS follow-up-care named contents. Not a fourth printout section.
How late effects are managed
ACS follow-up-care page says long-term side effects begin during treatment and continue after, and late side effects can start months or years later. Follow-up care may include a review of symptoms, a physical exam, blood tests to check blood counts and how the liver, kidneys, and other organs are working, and other tests as needed. Special tests after some treatments stay named on this printout. Those named steps are not encoded. Not a lab-panel, visit-interval, or screening engine.
ACS follow-up-care named steps. Not a fourth printout section.
Late toxicity printout — Breast
Breast
5 acute · 20 late · 18 monitor
Acute: ACS names fatigue, field skin change, soreness, and swelling during breast RT. Late: skin and size change, heart and lung problems, uncommon rib fracture, lasting fatigue, bone loss after hormone-affecting treatment, low estrogen or testosterone, lymphedema, jaw osteonecrosis after bisphosphonates, neuropathy after chemo, cognitive change after chemo, and vision change after hormone therapy. Monitor: new breast change after about a year; echoes after cardiotoxic chemo; yearly mammograms plus breast MRIs after chest radiation before age 30; lasting fatigue or sleep problems; dental check before bisphosphonates; numbness or tingling after chemo; memory, thinking, or focus change after chemo; vision change after hormone therapy. Those names are not encoded. Not a DXA-interval, Lung-RADS, or second-primary screening engine.
ACS long-term late names
Cancer-related fatigue that lasts · Joint or muscle pain after some treatments · Mental health and distress after treatment · Osteoporosis after hormone-affecting treatment · Low estrogen or testosterone after hormone-affecting treatment · Osteonecrosis of the jaw after bisphosphonates · Vision change after hormone therapy · Cavities and tooth loss after chemo · Peripheral neuropathy after chemo · Cognitive impairment after brain RT or chemo · Heart problems after some cardiotoxic treatments · Lymphedema after lymph-node surgery or radiation · Lymphedema after node surgery or RT
ACS follow-up tests named here
Echoes after cardiotoxic chemo · Yearly mammograms plus breast MRIs after chest radiation before age 30
Named conditions to monitor
New breast change after about a year · Lymphedema that does not settle · Chest-RT cardiac and breast-imaging flags · Second-cancer testing after breast cancer · Bone density after hormone-affecting treatment · Hot flashes, bone loss, or sex-hormone change after hormone-affecting treatment · Dental check before bisphosphonates · Vision change after hormone therapy · Cavity risk after chemo · Numbness or tingling in the feet or hands after chemo · New or worsening memory, thinking, or focus · New heart symptoms years after cardiotoxic treatment · New swelling after lymph-node surgery or radiation · Cancer-related fatigue or sleep problems that last · Joint or muscle pain after chemo, steroids, or hormone therapy · Anxiety, depression, or fear of recurrence after treatment · Second-cancer awareness after radiation or chemo · Ask which late-effect tests belong on the follow-up plan
Cadences are placeholders. Named tests are not encoded. Cited ACS / COG / ASCO names only. Complementary ACS long-term page is named, not encoded. Not a lymphedema stage engine. Not dose reconstruction. No invented trial percent.
Open printout →Late toxicity printout — Prostate
Prostate
5 acute · 17 late · 14 monitor
Acute: ACS names fatigue, pelvic-field skin change, short-term rectal and bladder problems, and nausea. Late: radiation proctitis and cystitis, incontinence, fertility and sexual side effects, low testosterone, osteoporosis, heart problems after ADT, lasting fatigue, jaw osteonecrosis after bisphosphonates, and vision change after hormone therapy. Monitor: lingering rectal or bladder symptoms after 3 to 6 months; echoes after cardiotoxic chemo; lasting fatigue or sleep problems; dental check before bisphosphonates; vision change after hormone therapy; a treatment summary. Those names are not encoded. First-row prostate toxicity stays empty on purpose. Not a PSA-kinetics or testosterone engine.
ACS long-term late names
Low testosterone after pelvic treatment or ADT · Osteoporosis after hormone-affecting treatment · Low estrogen or testosterone after hormone-affecting treatment · Osteonecrosis of the jaw after bisphosphonates · Vision change after hormone therapy · Heart problems after ADT · Heart problems after some cardiotoxic treatments · Cancer-related fatigue that lasts · Joint or muscle pain after some treatments · Mental health and distress after treatment
ACS follow-up tests named here
Echoes after cardiotoxic chemo
Named conditions to monitor
Radiation proctitis after 3 to 6 months · Radiation cystitis · PSA after treatment · Bone and heart health after ADT · Bone density after hormone-affecting treatment · Hot flashes, bone loss, or sex-hormone change after hormone-affecting treatment · New heart symptoms years after cardiotoxic treatment · Dental check before bisphosphonates · Vision change after hormone therapy · Cancer-related fatigue or sleep problems that last · Joint or muscle pain after chemo, steroids, or hormone therapy · Anxiety, depression, or fear of recurrence after treatment · Second-cancer awareness after radiation or chemo · Ask which late-effect tests belong on the follow-up plan
Cadences are placeholders. Named tests are not encoded. Cited ACS pelvis / prostate names only. Complementary ACS long-term page is named, not encoded. First-row prostate toxicity stays empty on purpose. No invented trial percent.
Open printout →Late toxicity printout — Head and neck
Head and neck
6 acute · 17 late · 11 monitor
Acute: ACS names fatigue, mouth or throat sores, dry mouth, swallowing trouble, nausea, earaches, and swelling. Late: lasting dry mouth, tooth decay, jaw stiffness, thyroid problems, jaw osteonecrosis, lymphedema, hearing or vision change, and lasting fatigue. Monitor: dental check before RT; a dentist at least once every 6 months after cavity-risk treatment; yearly thyroid exam after head, neck, or throat radiation; lasting fatigue or sleep problems. Those names are not encoded. Official lifetime figures are not restated. Not a dental-calendar, thyroid-lab, or oral visual-screen engine.
ACS long-term late names
Lymphedema after neck-node surgery or RT · Hearing loss after head RT or platinum chemo · Vision change after head or eye RT · Cancer-related fatigue that lasts · Joint or muscle pain after some treatments · Mental health and distress after treatment · Low thyroid hormones after head or neck radiation · Lymphedema after lymph-node surgery or radiation
ACS follow-up tests named here
Yearly thyroid exam after head, neck, or throat radiation
Named conditions to monitor
Mouth care and dental check before RT · Ongoing dry mouth and cavities · Thyroid after neck RT · Dental visits after head-and-neck treatment · Cancer-related fatigue or sleep problems that last · Joint or muscle pain after chemo, steroids, or hormone therapy · Anxiety, depression, or fear of recurrence after treatment · Fatigue, hair loss, or feeling colder after head or neck radiation · New swelling after lymph-node surgery or radiation · Second-cancer awareness after radiation or chemo · Ask which late-effect tests belong on the follow-up plan
Cadences are placeholders. Named tests are not encoded. Cited ACS head-and-neck names only. Complementary ACS long-term page is named, not encoded. Not a dysphagia-score or dental-interval engine. Official lifetime-risk figures are not restated. No invented trial percent.
Open printout →Late toxicity printout — Lung
Lung
5 acute · 16 late · 15 monitor
Acute: ACS names fatigue, chest-field skin change, sore throat, cough, shortness of breath, and heartburn or nausea. Late: radiation pneumonitis, pulmonary fibrosis, heart problems after chest or lung RT, lung problems after bleomycin, busulfan, or chest RT, lasting fatigue, hearing loss after high-dose platinum chemo, neuropathy after chemo, and cognitive change after chemo. Monitor: pneumonitis about 3 to 6 months after chest RT; lung function tests after some chemo or transplant; echoes after cardiotoxic chemo; yearly mammograms plus breast MRIs after chest radiation before age 30; lasting fatigue or sleep problems; hearing change after high-dose platinum chemo; numbness or tingling after chemo; memory, thinking, or focus change after chemo. Those names are not encoded. Not a Lung-RADS engine.
ACS long-term late names
Heart problems after chest or lung RT · Lung problems after bleomycin, busulfan, or chest RT · Cancer-related fatigue that lasts · Joint or muscle pain after some treatments · Mental health and distress after treatment · Hearing loss after high-dose platinum chemo · Cavities and tooth loss after chemo · Peripheral neuropathy after chemo · Cognitive impairment after brain RT or chemo · Heart problems after some cardiotoxic treatments
ACS follow-up tests named here
Lung function tests after some chemo or a stem-cell or bone-marrow transplant · Echoes after cardiotoxic chemo · Yearly mammograms plus breast MRIs after chest radiation before age 30
Named conditions to monitor
Radiation pneumonitis · Heart after mid-chest RT · Second-cancer testing · Pulmonologist after breathing change · Cancer-related fatigue or sleep problems that last · Joint or muscle pain after chemo, steroids, or hormone therapy · Anxiety, depression, or fear of recurrence after treatment · Hearing change after high-dose platinum chemo · Cavity risk after chemo · Numbness or tingling in the feet or hands after chemo · New or worsening memory, thinking, or focus · New heart symptoms years after cardiotoxic treatment · Cough, shortness of breath, or wheezing after lung-toxic treatment · Second-cancer awareness after radiation or chemo · Ask which late-effect tests belong on the follow-up plan
Cadences are placeholders. Named tests are not encoded. Cited ACS chest / lung names only. Complementary ACS long-term page is named, not encoded. Not a Lung-RADS or heart-dose engine. No invented trial percent.
Open printout →Late toxicity printout — Brain
Brain
6 acute · 15 late · 12 monitor
Acute: ACS names headaches, nausea, fatigue, hair and scalp change, hearing loss, dizziness, seizures, and short-term memory or speech trouble. Late: memory loss, stroke-like symptoms, poor brain function, radiation necrosis, cognitive change, hearing or vision change, lasting fatigue, cavities after head RT or chemo, and low thyroid hormones after head radiation. Monitor: same-day report of headache during RT; later effects from 6 months to years; yearly thyroid exam after head, neck, or throat radiation; lasting fatigue or sleep problems; cavity risk after head RT or chemo. Those names are not encoded. The cited adult after-treatment page still has no official later-cancer sentence. Not an MRI screening engine.
The cited adult brain after-treatment page still has no official later-cancer sentence.
ACS long-term late names
Cognitive impairment after brain RT or chemo · Hearing loss after brain RT or platinum chemo · Vision change after head or eye RT · Cancer-related fatigue that lasts · Joint or muscle pain after some treatments · Mental health and distress after treatment · Cavities and tooth loss after head RT or chemo · Low thyroid hormones after head or neck radiation
ACS follow-up tests named here
Yearly thyroid exam after head, neck, or throat radiation
Named conditions to monitor
Headache or new neurologic change during RT · Delayed brain effects · Stereotactic single-dose timing · New or worsening memory, hearing, or vision change · New or worsening memory, thinking, or focus · Cancer-related fatigue or sleep problems that last · Joint or muscle pain after chemo, steroids, or hormone therapy · Anxiety, depression, or fear of recurrence after treatment · Cavity risk after head RT or chemo · Fatigue, hair loss, or feeling colder after head or neck radiation · Second-cancer awareness after radiation or chemo · Ask which late-effect tests belong on the follow-up plan
Cadences are placeholders. Named tests are not encoded. Cited ACS brain-RT names only. Complementary ACS long-term page is named, not encoded. The cited adult brain after-treatment page has no official later-cancer sentence. Not an MRI screening or necrosis-volume engine. No invented trial percent.
Open printout →Late toxicity printout — GI
GI
5 acute · 16 late · 13 monitor
Acute: ACS names nausea, heartburn, cramps, diarrhea or constipation, bowel urgency, and rectal or anal skin irritation. Late: radiation proctitis, bowel incontinence, ostomy or chronic bowel change, neuropathy, adhesions, urinary trouble after pelvis RT, fertility effects, sexuality changes, lasting fatigue, cavities after chemo, and cognitive change after chemo. Monitor: on-treatment diarrhea; proctitis after 3 to 6 months; lasting fatigue or sleep problems; sexuality or body-image change; fertility after pelvis, belly, or spine treatment; cavity risk after chemo; memory, thinking, or focus change after chemo; a treatment summary and second-cancer watching. Those names are not encoded. Official esophagus share-of-new-cases figures are not restated. Not a Lynch or endoscopy engine.
ACS long-term late names
Bowel obstruction from adhesions · Urinary retention or incontinence after pelvis RT · Fertility after pelvis, belly, or spine RT · Sexuality after cancer treatment · Cancer-related fatigue that lasts · Joint or muscle pain after some treatments · Mental health and distress after treatment · Cavities and tooth loss after chemo · Cognitive impairment after brain RT or chemo
Named conditions to monitor
Diarrhea that starts during abdomen RT · Radiation proctitis after 3 to 6 months · Second-cancer testing · Bowel blockage or bladder-emptying trouble · Cancer-related fatigue or sleep problems that last · Joint or muscle pain after chemo, steroids, or hormone therapy · Anxiety, depression, or fear of recurrence after treatment · Sexuality or body-image change after treatment · Fertility after pelvis, belly, or spine treatment · Cavity risk after chemo · New or worsening memory, thinking, or focus · Second-cancer awareness after radiation or chemo · Ask which late-effect tests belong on the follow-up plan
Cadences are placeholders. Named tests are not encoded. Cited ACS abdomen / pelvis / CRC names only. Complementary ACS long-term page is named, not encoded. Official esophagus share-of-new-cases figures are not restated. No invented trial percent.
Open printout →Late toxicity printout — GYN
GYN
5 acute · 17 late · 12 monitor
Acute: ACS names fatigue, pelvic-field skin change, short-term rectal and bladder problems, nausea, and vaginal or vulvar field irritation. Late: radiation proctitis and cystitis, incontinence, fistula, menopause symptoms, fertility effects, low estrogen, osteoporosis, lymphedema, lasting fatigue, jaw osteonecrosis after bisphosphonates, and vision change after hormone therapy. Monitor: pelvic bleeding, pain, or leakage after RT; regular cervical screening may be named; lasting fatigue or sleep problems; dental check before bisphosphonates; vision change after hormone therapy; a treatment summary. Those names are not encoded. GTD stays out of domain. First-row cervix toxicity stays empty on purpose. Not a CA-125, HPV-dose, or ASCCP engine.
ACS long-term late names
Low estrogen after pelvic treatment · Osteoporosis after hormone-affecting treatment · Low estrogen or testosterone after hormone-affecting treatment · Osteonecrosis of the jaw after bisphosphonates · Vision change after hormone therapy · Lymphedema after pelvic-node surgery or RT · Cancer-related fatigue that lasts · Joint or muscle pain after some treatments · Mental health and distress after treatment
Named conditions to monitor
Pelvic bleeding, pain, or leakage after RT · Menopause symptoms · Cervix first-row toxicity · Bone density after hormone-affecting treatment · Hot flashes, bone loss, or sex-hormone change after hormone-affecting treatment · Dental check before bisphosphonates · Vision change after hormone therapy · Cancer-related fatigue or sleep problems that last · Joint or muscle pain after chemo, steroids, or hormone therapy · Anxiety, depression, or fear of recurrence after treatment · Second-cancer awareness after radiation or chemo · Ask which late-effect tests belong on the follow-up plan
Cadences are placeholders. Named tests are not encoded. Adult GYN RT fields only. Gestational trophoblastic disease is out of domain. Complementary ACS long-term page is named, not encoded. Not a CA-125 or ASCCP engine. No invented trial percent.
Open printout →Late toxicity printout — Skin
Skin
4 acute · 10 late · 9 monitor
Acute: ACS names field dermatitis, fatigue, hair loss in the field, and tenderness. Late: darker or more sensitive skin, texture change, field-skin counseling after chest RT, another skin cancer in or near the field, and lasting fatigue. Monitor: field infection during RT; new or changing lesions; lasting fatigue or sleep problems; a treatment summary. Those names are not encoded. Keratinocyte carcinoma stays labeled separately. Not a population visual-screen engine.
ACS long-term late names
Cancer-related fatigue that lasts · Joint or muscle pain after some treatments · Mental health and distress after treatment · Treatment summary for later problems
Named conditions to monitor
Field infection or severe dermatitis · New or changing lesion after melanoma or keratinocyte RT · Second-cancer testing after melanoma · Ask for a treatment summary · Cancer-related fatigue or sleep problems that last · Joint or muscle pain after chemo, steroids, or hormone therapy · Anxiety, depression, or fear of recurrence after treatment · Second-cancer awareness after radiation or chemo · Ask which late-effect tests belong on the follow-up plan
Cadences are placeholders. Named tests are not encoded. Cited ACS field-skin and melanoma / BCC names only. Complementary ACS long-term page is named, not encoded. Keratinocyte stays labeled separately. No invented NCCN month table.
Open printout →Late toxicity printout — Lymphoma / myeloma fields
Lymphoma / myeloma fields
5 acute · 23 late · 19 monitor
Acute: ACS names fatigue, field skin change, sore throat, nausea, and low blood counts. Late: heart and lung problems after chest-field RT or named cardiotoxic or lung-toxic drugs, thyroid problems after neck-field RT, breast-imaging after chest RT, lasting fatigue, bowel or bladder problems after abdomen or pelvis treatment, hearing loss after high-dose platinum chemo, fertility effects, sexuality changes, neuropathy after chemo, and cognitive change after chemo. Monitor: COG / ASCO echo flags; yearly thyroid exam; lung function tests after some chemo or transplant; yearly mammograms plus breast MRIs after chest radiation before age 30; lasting fatigue or sleep problems; bowel or bladder change after abdomen or pelvis treatment; hearing change after high-dose platinum chemo; fertility after pelvis, belly, or spine treatment; sexuality or body-image change; numbness or tingling after chemo; memory, thinking, or focus change after chemo. Those names are not encoded. Hodgkin stays Ann Arbor. Official Stage I percent-of-cases cells are not restated. Anthracycline and bleomycin stay unnamed as myeloma-specific. Not an AML or PET/CT engine.
Anthracycline and bleomycin stay unnamed as myeloma-specific.
ACS long-term late names
Heart problems after anthracyclines or chest RT · Lung problems after bleomycin or chest RT · Second cancers after chemo or chest RT · Cancer-related fatigue that lasts · Joint or muscle pain after some treatments · Mental health and distress after treatment · Bowel or bladder problems after abdomen or pelvis treatment · Hearing loss after high-dose platinum chemo · Cavities and tooth loss after chemo · Peripheral neuropathy after chemo · Cognitive impairment after brain RT or chemo · Heart problems after some cardiotoxic treatments · Low thyroid hormones after head or neck radiation · Lung problems after bleomycin, busulfan, or chest RT · Fertility after pelvis, belly, or spine RT · Sexuality after cancer treatment
ACS follow-up tests named here
Yearly thyroid exam after head, neck, or throat radiation · Lung function tests after some chemo or a stem-cell or bone-marrow transplant · Echoes after cardiotoxic chemo · Yearly mammograms plus breast MRIs after chest radiation before age 30
Named conditions to monitor
Anthracycline echo and chest-RT flags · Breast imaging after chest RT before age 30 · Second-cancer testing · Cardiologist or pulmonologist after named cardiotoxic or lung-toxic treatment · Cancer-related fatigue or sleep problems that last · Joint or muscle pain after chemo, steroids, or hormone therapy · Anxiety, depression, or fear of recurrence after treatment · Bowel or bladder change after abdomen or pelvis treatment · Hearing change after high-dose platinum chemo · Cavity risk after chemo · Numbness or tingling in the feet or hands after chemo · New or worsening memory, thinking, or focus · New heart symptoms years after cardiotoxic treatment · Fatigue, hair loss, or feeling colder after head or neck radiation · Cough, shortness of breath, or wheezing after lung-toxic treatment · Fertility after pelvis, belly, or spine treatment · Sexuality or body-image change after treatment · Second-cancer awareness after radiation or chemo · Ask which late-effect tests belong on the follow-up plan
Cadences are placeholders. Named tests are not encoded. Cited ACS / COG / ASCO field names only. Complementary ACS long-term page is named, not encoded. Hodgkin stays Ann Arbor, not localized/regional/distant. No dose reconstruction. Official Stage I percent-of-cases cells are not restated.
Open printout →Late toxicity printout — Sarcoma
Sarcoma
4 acute · 19 late · 18 monitor
Acute: ACS names fatigue, field dermatitis, hair loss in the field, and pain or swelling. Late: skin and fibrosis change, lymphedema, heart problems after anthracyclines, neuropathy, fertility effects, sexuality changes, lasting fatigue, bowel or bladder problems after abdomen or pelvis treatment, hearing loss after high-dose platinum chemo, and cognitive change after chemo. Monitor: field wound or infection; later heart checks after some sarcoma chemo; echoes after cardiotoxic chemo; lung function tests after some chemo or transplant; lasting fatigue or sleep problems; bowel or bladder change after abdomen or pelvis treatment; hearing change after high-dose platinum chemo; fertility after pelvis, belly, or spine treatment; sexuality or body-image change; memory, thinking, or focus change after chemo. Those names are not encoded. Official age-band percent-of-cases cells are not restated. Female death rate stays a rate per 100k. Not a fracture-risk or second-primary screening engine.
ACS long-term late names
Heart problems after anthracyclines · Heart problems after some cardiotoxic treatments · Peripheral neuropathy after chemo · Cognitive impairment after brain RT or chemo · Fertility after pelvis, belly, or spine RT · Sexuality after cancer treatment · Cancer-related fatigue that lasts · Joint or muscle pain after some treatments · Mental health and distress after treatment · Bowel or bladder problems after abdomen or pelvis treatment · Hearing loss after high-dose platinum chemo · Cavities and tooth loss after chemo
ACS follow-up tests named here
Echoes after cardiotoxic chemo · Lung function tests after some chemo or a stem-cell or bone-marrow transplant
Named conditions to monitor
Field wound or infection · Later heart checks after some sarcoma chemo · Soft-tissue sarcoma follow-up · Second-cancer testing after soft-tissue sarcoma · Treatment-related second-cancer risk after some bone sarcoma therapy · Nerve and fertility effects after some sarcoma therapy · Cancer-related fatigue or sleep problems that last · Joint or muscle pain after chemo, steroids, or hormone therapy · Anxiety, depression, or fear of recurrence after treatment · Bowel or bladder change after abdomen or pelvis treatment · Hearing change after high-dose platinum chemo · Cavity risk after chemo · Fertility after pelvis, belly, or spine treatment · Sexuality or body-image change after treatment · New or worsening memory, thinking, or focus · New heart symptoms years after cardiotoxic treatment · Second-cancer awareness after radiation or chemo · Ask which late-effect tests belong on the follow-up plan
Cadences are placeholders. Named tests are not encoded. Bone and soft-tissue are cited sarcoma algorithm sites. Complementary ACS long-term page is named, not encoded. Official bone and soft-tissue age-band percent-of-cases cells are not restated. Female soft-tissue death rate stays a rate per 100k. No invented trial percent.
Open printout →